Shutish Patel, MD
Neurology · New Britain,, CTNPI 1447273511
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,505 of the $73,320 with a category attached, or 90.7%. AbbVie accounts for 97.5% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $22,667 and has fallen 58.2% since, to $9,469 in 2024.
Across 249 payments — averaging $294.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$71K
- Amgen$360
- CSL Behring$220
- SK Life Science, Inc.$198
- MDD US Operations, LLC$193
- AstraZeneca$126
- plus $730 from 11 others
What the payments were for
- Speaking & faculty fees$66,50591%
- Travel & lodging$8331%
- Food & beverage$5,8618%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 211 | $71,494 |
| Amgen(2 entities) | 9 | $360 |
| CSL Behring | 3 | $220 |
| SK Life Science, Inc. | 4 | $198 |
| MDD US Operations, LLC | 5 | $193 |
| AstraZeneca | 1 | $126 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $122 |
| Akcea Therapeutics, Inc. | 1 | $122 |
| Biogen | 2 | $117 |
| EMD Serono, Inc. | 1 | $100 |
| E.r. Squibb & Sons, L.L.C. | 1 | $98 |
| Pfizer | 3 | $60 |
| Upsher-smith Laboratories LLC | 2 | $36 |
| Novartis | 1 | $23 |
| UCB, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Adamas Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,320 in reported general payments places this provider in the 85th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 32 | $51,476 |
| UbrelvyUbrogepant | 38 | $47,207 |
| VimpatLacosamide | 28 | $31,337 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $26,643 |
| QuliptaAtogepant | 18 | $20,297 |
| Emgality PenGalcanezumab-Gnlm | 11 | $14,522 |
| LamictalLamotrigine | 20 | $13,374 |
| Rasagiline Mesylate | 33 | $6,890 |
| Gabapentin | 354 | $6,006 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 160 | $4,215 |
| Levetiracetam | 134 | $3,490 |
| Dimethyl Fumarate | 21 | $2,926 |
| Metaxalone | 11 | $2,664 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $2,425 |
| Primidone | 56 | $1,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $71,494 | $67,50556 claims |
| PfizerNurtec Odt | $60 | $51,47632 claims |
| UCB, Inc.Vimpat | $22 | $31,33728 claims |
| Upsher-smith Laboratories LLCTopiramate | $36 | $69092 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 280 neurology providers in Connecticut.
Other neurology in New Britain,
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Duarte MachadoCheshire$426K
- Tanya BilchikEast Hartford$361K
- Peter GottschalkFairfield$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.